Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down – Time to Sell?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) gapped down before the market opened on Thursday . The stock had previously closed at $7.24, but opened at $7.06. Recursion Pharmaceuticals shares last traded at $7.13, with a volume of 2,351,590 shares traded.

Wall Street Analyst Weigh In

Several analysts recently weighed in on RXRX shares. Jefferies Financial Group reduced their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Finally, Leerink Partners lowered their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $9.25.

Recursion Pharmaceuticals Stock Up 3.6 %

The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of -4.90 and a beta of 0.85. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a 50 day moving average price of $6.78 and a 200 day moving average price of $7.16.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. During the same quarter last year, the business earned ($0.43) earnings per share. Recursion Pharmaceuticals’s revenue was up 147.6% compared to the same quarter last year. As a group, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Activity at Recursion Pharmaceuticals

In related news, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total value of $123,200.00. Following the completion of the sale, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at $4,697,960.96. The trade was a 2.56 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $6.22, for a total value of $71,200.34. Following the transaction, the director now directly owns 7,098,428 shares in the company, valued at approximately $44,152,222.16. This trade represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 101,788 shares of company stock worth $682,691 in the last 90 days. Corporate insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. ARK Investment Management LLC raised its holdings in shares of Recursion Pharmaceuticals by 16.4% in the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after acquiring an additional 4,626,268 shares during the last quarter. State Street Corp raised its stake in shares of Recursion Pharmaceuticals by 47.1% in the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after purchasing an additional 4,120,685 shares during the last quarter. Lingotto Investment Management LLP raised its stake in shares of Recursion Pharmaceuticals by 69.0% in the second quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock worth $27,563,000 after purchasing an additional 1,500,000 shares during the last quarter. Ghisallo Capital Management LLC purchased a new position in shares of Recursion Pharmaceuticals during the second quarter valued at approximately $8,250,000. Finally, Perceptive Advisors LLC purchased a new position in shares of Recursion Pharmaceuticals during the second quarter valued at approximately $5,769,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.